 James Cooper
Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Rejection | 18 | 2020 | 516 | 4.830 |
Why?
| | Kidney Transplantation | 19 | 2020 | 541 | 4.760 |
Why?
| | Isoantibodies | 10 | 2020 | 57 | 3.680 |
Why?
| | HLA Antigens | 10 | 2020 | 224 | 3.260 |
Why?
| | Graft Survival | 14 | 2020 | 452 | 3.090 |
Why?
| | Immunosuppressive Agents | 13 | 2020 | 647 | 2.570 |
Why?
| | Tacrolimus | 5 | 2020 | 134 | 2.030 |
Why?
| | Histocompatibility | 4 | 2017 | 26 | 1.320 |
Why?
| | Pancreas Transplantation | 4 | 2017 | 61 | 1.190 |
Why?
| | Kidney Failure, Chronic | 4 | 2017 | 487 | 0.950 |
Why?
| | Immunoglobulins, Intravenous | 3 | 2014 | 122 | 0.930 |
Why?
| | Tissue Donors | 3 | 2017 | 317 | 0.910 |
Why?
| | Drug Monitoring | 2 | 2020 | 184 | 0.740 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 58 | 0.690 |
Why?
| | Boronic Acids | 2 | 2010 | 33 | 0.660 |
Why?
| | Pyrazines | 2 | 2010 | 71 | 0.640 |
Why?
| | Acute Disease | 6 | 2020 | 912 | 0.610 |
Why?
| | Transplantation, Homologous | 3 | 2011 | 386 | 0.460 |
Why?
| | Time Factors | 9 | 2020 | 6124 | 0.400 |
Why?
| | Treatment Outcome | 10 | 2020 | 9089 | 0.390 |
Why?
| | Nephritis, Interstitial | 1 | 2010 | 7 | 0.360 |
Why?
| | BK Virus | 1 | 2010 | 14 | 0.360 |
Why?
| | Polyomavirus Infections | 1 | 2010 | 22 | 0.350 |
Why?
| | Protease Inhibitors | 1 | 2010 | 97 | 0.320 |
Why?
| | Antibodies | 1 | 2011 | 371 | 0.320 |
Why?
| | Risk Assessment | 5 | 2020 | 2973 | 0.320 |
Why?
| | Risk Factors | 6 | 2020 | 8627 | 0.290 |
Why?
| | Acute Kidney Injury | 1 | 2013 | 637 | 0.280 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1796 | 0.270 |
Why?
| | Histocompatibility Testing | 2 | 2020 | 118 | 0.270 |
Why?
| | Biomarkers | 5 | 2020 | 3416 | 0.260 |
Why?
| | Colorado | 5 | 2017 | 4086 | 0.220 |
Why?
| | Retrospective Studies | 7 | 2020 | 12515 | 0.220 |
Why?
| | Humans | 18 | 2020 | 114756 | 0.220 |
Why?
| | Chronic Disease | 3 | 2014 | 1590 | 0.210 |
Why?
| | Monitoring, Immunologic | 2 | 2014 | 23 | 0.210 |
Why?
| | Prognosis | 4 | 2017 | 3334 | 0.200 |
Why?
| | Female | 13 | 2020 | 59507 | 0.200 |
Why?
| | Male | 13 | 2020 | 55579 | 0.200 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 604 | 0.190 |
Why?
| | Middle Aged | 8 | 2020 | 26757 | 0.180 |
Why?
| | HLA-DR Antigens | 1 | 2020 | 220 | 0.170 |
Why?
| | Bortezomib | 2 | 2010 | 41 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 2 | 2011 | 815 | 0.160 |
Why?
| | Creatinine | 2 | 2011 | 424 | 0.150 |
Why?
| | Desensitization, Immunologic | 1 | 2019 | 117 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 268 | 0.140 |
Why?
| | Kidney Function Tests | 1 | 2017 | 140 | 0.140 |
Why?
| | Transplantation Immunology | 1 | 2016 | 30 | 0.140 |
Why?
| | Mycophenolic Acid | 1 | 2017 | 77 | 0.140 |
Why?
| | Hospitals, University | 2 | 2017 | 171 | 0.140 |
Why?
| | Decision Support Techniques | 1 | 2020 | 351 | 0.130 |
Why?
| | Biopsy | 2 | 2010 | 1040 | 0.130 |
Why?
| | Survival Rate | 2 | 2017 | 1642 | 0.130 |
Why?
| | Postoperative Complications | 2 | 2017 | 2127 | 0.120 |
Why?
| | Adult | 7 | 2020 | 30548 | 0.120 |
Why?
| | Transplant Recipients | 1 | 2016 | 140 | 0.120 |
Why?
| | Primary Prevention | 1 | 2016 | 172 | 0.120 |
Why?
| | Preoperative Care | 1 | 2016 | 317 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 359 | 0.120 |
Why?
| | Delayed Graft Function | 1 | 2013 | 26 | 0.110 |
Why?
| | Tissue and Organ Harvesting | 1 | 2013 | 62 | 0.110 |
Why?
| | Donor Selection | 1 | 2013 | 66 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4420 | 0.110 |
Why?
| | Cyclosporine | 1 | 2013 | 161 | 0.110 |
Why?
| | Algorithms | 1 | 2020 | 1468 | 0.100 |
Why?
| | Cell-Derived Microparticles | 1 | 2013 | 57 | 0.100 |
Why?
| | Preoperative Period | 1 | 2013 | 103 | 0.100 |
Why?
| | Seroepidemiologic Studies | 1 | 2013 | 138 | 0.100 |
Why?
| | Postoperative Period | 1 | 2013 | 289 | 0.100 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 429 | 0.090 |
Why?
| | Reoperation | 2 | 2010 | 514 | 0.090 |
Why?
| | Transplantation Tolerance | 1 | 2011 | 31 | 0.090 |
Why?
| | Prospective Studies | 2 | 2013 | 6217 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2010 | 40 | 0.090 |
Why?
| | Antilymphocyte Serum | 1 | 2009 | 65 | 0.080 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2010 | 134 | 0.080 |
Why?
| | Immunity, Humoral | 1 | 2010 | 112 | 0.080 |
Why?
| | Endothelial Cells | 1 | 2013 | 681 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 770 | 0.080 |
Why?
| | Virus Replication | 1 | 2010 | 395 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2011 | 1086 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1521 | 0.070 |
Why?
| | Hypertension | 1 | 2015 | 1059 | 0.070 |
Why?
| | United States | 1 | 2020 | 12176 | 0.060 |
Why?
| | Mass Screening | 1 | 2011 | 1003 | 0.060 |
Why?
| | Young Adult | 2 | 2010 | 10463 | 0.060 |
Why?
| | Prednisone | 1 | 2017 | 231 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 122 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 954 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 2 | 0.030 |
Why?
| | Complement C3 | 1 | 2013 | 189 | 0.030 |
Why?
| | Aged | 1 | 2010 | 19094 | 0.030 |
Why?
| | Complement Activation | 1 | 2013 | 340 | 0.020 |
Why?
| | HLA-D Antigens | 1 | 2009 | 34 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1717 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2312 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2009 | 174 | 0.020 |
Why?
| | Rabbits | 1 | 2009 | 736 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2890 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2539 | 0.020 |
Why?
| | Risk | 1 | 2009 | 815 | 0.020 |
Why?
| | Kidney | 1 | 2013 | 1184 | 0.020 |
Why?
| | Survivors | 1 | 2009 | 411 | 0.020 |
Why?
| | Patient Selection | 1 | 2009 | 641 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1846 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4710 | 0.010 |
Why?
| | Patient Discharge | 1 | 2009 | 769 | 0.010 |
Why?
| | Animals | 2 | 2013 | 31761 | 0.010 |
Why?
| | Mice | 1 | 2013 | 14916 | 0.010 |
Why?
| | Child | 1 | 2015 | 18352 | 0.010 |
Why?
|
|
Cooper's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|